TM6SF2 and hepatocellular carcinoma: A study of a large cohort of DAAs-treated patients with CHC and cirrhosis showed that a genetic risk score (GRS) combining hepatic fat accumulation with variants in PNPLA3 (patatin-like phospholipase domain containing 3), MBOAT7 (membrane bound O-acyltransferase domain containing 7), TM6SF2 (transmembrane 6 superfamily member 2) and GCKR (glucokinase regulator) associated with HCC development independently of classical risk factors, including liver disease severity [31].